VKTX Stock Forecast: Viking Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$25
−4.12% on the day

The median 12-month analyst price target for Viking Therapeutics, Inc. is $95. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$3.3B
Ticker Nerd rank
13/ 100
Median analyst target
$95
Analysts covering
21
Revenue$0.0
Operating income−$132.6M
Net income−$128.0M
Free cash flow−$125.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.2%
1M
−7.2%
YTD
−29.6%
1Y
−27.7%
From 52W high
−41.2%
From 52W low
+2.3%
$24
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
13/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
65
Accruals
53
Volatility
49
Momentum
43
Quality
25
Revisions
23
Growth
17
Issuance
10

Value (65): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VKTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26VKTXHigh $125Median $95Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
19
Buy
2
Hold
0
Sell
$34
Low
$95
Median
$125
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
31 Oct 2026Canaccord GenuityMaintainsBuy—
30 Oct 2026Canaccord GenuityMaintainsBuy$106 → $118
20 Oct 2026Canaccord GenuityMaintainsBuy$114 → $106
15 Oct 2026UBSInitiatesBuy$94
7 Oct 2026Truist SecuritiesMaintainsBuy$87 → $85
23 Sept 2026Truist SecuritiesMaintainsBuy$83 → $87
11 Aug 2026JP MorganMaintainsOverweight$75 → $65
30 July 2026Canaccord GenuityMaintainsBuy$107 → $114
28 May 2026Lake StreetInitiatesBuy$89
1 May 2026BTIGReiteratesBuy—
30 Apr 2026Cantor FitzgeraldMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025Canaccord GenuityMaintainsBuy—
29 Oct 2025Canaccord GenuityInitiatesBuy—
24 Oct 2025JP MorganMaintainsOverweight—
23 Oct 2025Morgan StanleyMaintainsOverweight—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Sept 2025BTIGReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
24 July 2025CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VKTX.

Market Radar

This page is one stock. Monday covers all of them.

VKTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VKTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Viking Therapeutics, Inc. returned −27.7% against +6.9% for the S&P 500, dividends included.

VKTX vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26VKTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VKTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
10
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
5.7×

Cheaper than 15% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−96.4%

Higher than 14% of US stocks

Return on assets
−47.2%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viking Therapeutics, Inc. has a market value of $3.3B and an enterprise value of $2.6B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$534.8M.

  • Diluted earnings per share, trailing twelve months: −$4.66.

  • Free cash flow in the twelve months to 30 June 2026: −$418.4M.

  • Shares outstanding: 116.7M.

  • Viking Therapeutics, Inc. employs 74 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

VKTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VKTXViking Therapeutics, Inc.$3.3B13
ABCLAbCellera Biologics, Inc.$3.1B78
IOVAIovance Biotherapeutics, Inc.$3.1B95
ARQTArcutis Biotherapeutics, Inc.$3.3B69
ADMAADMA Biologics, Inc.$2.9B60
ACADACADIA Pharmaceuticals, Inc.$2.9B84
VRDNViridian Therapeutics, Inc.$3.3B60

Take a look at VKTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VKTX

What is the VKTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Viking Therapeutics, Inc. is $95, with estimates ranging from $34 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VKTX stock a buy right now?

Of the 21 analysts covering Viking Therapeutics, Inc., 19 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VKTX?

As at 21 Nov 2026, Viking Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (65 of 100).

Will VKTX stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts is $95, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VKTX stock forecast for 2030?

No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $125 over the next 12 months.

How has VKTX stock performed over the past year?

Viking Therapeutics, Inc. returned -27.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viking Therapeutics, Inc. do?

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease.

Company

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.

CEO Dr. Brian Lian Ph.D. · 74 employees · United States · https://www.vikingtherapeutics.com